Bharat Biotech Ends Brazil Agreement With 2 Firms Amid Political Row | Read

  • 0:44
  • Published On: July 24, 2021
Cinema View
Embed
Drugmaker Bharat Biotech on Friday said it has scrapped agreements with two Brazilian companies amid controversy over a $324 million deal between the South American country and Bharat Biotech for the import of 20 million doses of the made-in-India COVID-19 vaccine Covaxin.

Related Videos

Bharat Biotech's Suchitra Ella On The Lessons From The Covid-19 Pandemic
April 14, 2023 8:47
Bharat Biotech's Nasal Vaccine Against Covid-19 Cleared For Use
September 06, 2022 2:57
3 Indian Vaccines Approved For Use On Children
April 27, 2022 3:35
Covaxin Cleared For 6-12 Age Group
April 26, 2022 2:47
Paid Boosters For All Adults From Today
April 10, 2022 4:00
Few Takers For Precautionary Dose At Private Hospitals In Chennai
April 10, 2022 3:37
WHO Suspends UN Supply Of Covaxin; No Impact On Efficacy: Bharat Biotech
April 03, 2022 0:37
Covaxin Maker Bharat Biotech's Nasal Booster Dose Trials Get Approval
January 28, 2022 2:00
Covishield, Covaxin Cleared For Market Approval By Expert Panel
January 19, 2022 8:12
The Biggest Stories Of January 19, 2022
January 19, 2022 15:32
Covaxin Cleared For 12+, But No Data Released Yet
December 26, 2021 9:18
Vaccines For At-Risk Children Next Month: Covid Panel Chief To NDTV
November 29, 2021 5:21
Our Offerings: NDTV
  • मध्य प्रदेश
  • राजस्थान
  • इंडिया
  • मराठी
  • 24X7
Choose Your Destination